Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone …
Jan 9, 2024 · Two years of adjuvant abemaciclib combined with endocrine therapy (ET) resulted in a significant improvement in invasive disease-free survival (IDFS) and distant relapse-free …
Abemaciclib plus endocrine therapy for hormone receptor …
Dec 6, 2022 · monarchE is an open-label, randomised phase 3 trial, which was run at 603 sites including hospitals, and academic and community centres in 38 countries (appendix pp 32–63).
Abemaciclib Combined With Endocrine Therapy for the Adjuvant ... - PubMed
Dec 1, 2020 · Abemaciclib is an oral, continuously dosed, CDK4/6 inhibitor approved for HR+, HER2- advanced breast cancer (ABC). Efficacy and safety of abemaciclib in ABC supported …
Sep 20, 2020 · eligible and randomly assigned (1:1) to standard-of-care adjuvant endocrine therapy (ET) with or without abemaciclib (150 mg twice daily for 2 years). The primary end …
Abemaciclib Combined With Endocrine Therapy for the Adjuvant …
Sep 20, 2020 · monarchE is an open-label, global, randomized, phase III trial that investigated the addition of abemaciclib to standard adjuvant ET in patients with HR+, HER2−, node-positive, …
Abstract OT2-02-02: MONARCH E: A phase 3 study of standard …
Feb 15, 2020 · Trial design: monarchE (NCT03155997) is a multicenter, randomized, open-label phase 3 trial evaluating adjuvant abemaciclib in patients with node-positive, high-risk, HR+, …
Adjuvant abemaciclib combined with endocrine therapy for high …
Mar 22, 2022 · In monarchE, abemaciclib plus endocrine therapy (ET) as adjuvant treatment of hormone receptor-positive, human epidermal growth factor 2-negative, high-risk, early breast …
Adjuvant abemaciclib combined with endocrine therapy for …
Oct 14, 2021 · To evaluate this important question, monarchE, an open-label, global, phase III, randomized trial comparing adjuvant ET for at least 5 years with or without abemaciclib for 2 …
Abemaciclib plus endocrine therapy for hormone receptor
Methods: In monarchE, an open-label, randomised, phase 3 trial, adult patients (aged ≥18 years) who had hormone receptor-positive, HER2-negative, node-positive, early breast cancer at a …
Overall Survival and Long-Term Outcomes in the monarchE Trial
Jan 18, 2024 · With a median follow-up of 54 months, the benefit of adding abemaciclib was sustained for invasive disease–free survival (HR = 0.680, 95% CI = 0.599–0.772; nominal P < …